- Alkermes press release ( NASDAQ: ALKS ): Q2 Non-GAAP EPS of $0.06 beats by $0.05 .
- Revenue of $276.2M (-9.1% Y/Y) beats by $7.19M .
-
"In the second quarter, Alkermes continued to execute successfully across the business. VIVITROL ® and ARISTADA ® both grew year-over-year and sequentially, and LYBALVI ® continued on a strong launch trajectory. Today, we are pleased to be raising our financial expectations for full-year 2022, primarily due to LYBALVI's launch performance and updated assumptions related to continued royalty revenues on sales of long-acting INVEGA ® products outside of the U.S. We believe that we are well positioned to continue to make meaningful progress against our strategic priorities and to drive shareholder value." commented Iain Brown, Chief Financial Officer of Alkermes.
For further details see:
Alkermes Non-GAAP EPS of $0.06 beats by $0.05, revenue of $276.2M beats by $7.19M